Source: Google NewsPublished on 2021-02-18
Related Articles:
- Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 - GlobeNewswire February 18, 2021 Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 GlobeNewswire
- Neuroprotective Mechanisms of Anavex 2-73 Revealed in Preclinical Study March 7, 2019 New preclinical data have shown for the first time the underlying mechanisms mediating the therapeutic activity of Anavex 2-73, an investigational therapy being evaluated for the treatment of neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). Anavex Life Sciences’ investigational activator of the sigma-1 receptor was found to exert its neuroprotective effect by re-establishing the normal functioning of cells’ “recycling…
- Anavex 2-73 Therapy Candidate Seen to Restore Brain Cell Function in Mice with Parkinson’s, Study Finds October 31, 2017 Anavex 2-73, an investigational therapy being evaluated in clinical trials for Alzheimer’s disease, was found to restore the function of damaged nerve cells in mouse models of Parkinson’s disease. Based on the favorable safety profile seen in the clinic, the findings support the hypothesis that Anavex 2-73 might be a promising approach for treating Parkinson’s disease patients. The preclinical findings were presented at…
- 2021: Wish list January 26, 2021 # # # # Here at the Science of Parkinson’s, we don’t like making predictions – that’s a fool’s game. We would rather focus our attention on interesting ideas and trends, discussing what we hope to see happen in the future, and exploring different ways and means by which change could occur. It is done in the hope that someone…
- Phase 2 Study of Potential Oral Therapy for Parkinson’s Dementia, Anavex 2-73, Planned April 20, 2018 Anavex Life Sciences is planning to open a Phase 2 clinical trial testing Anavex 2-73, a potential oral treatment for patients with Parkinson’s disease dementia (PDD), this year. Anavex 2-73 aims to treat PDD by binding to the sigma-1 receptor, located in a cellular structure called the endoplasmic reticulum and important to protein production and transport. The proposed double-blind, placebo-controlled trial will…
- Phase 2 Trial Testing Anavex 2-73 Recruiting Parkinson’s Patients With Dementia in Spain November 1, 2018 The first patient has been enrolled in Anavex Life Sciences‘ Phase 2 clinical trial to evaluate the potential and safety of Anavex 2-73 as a treatment for Parkinson’s disease dementia. Now actively recruiting, the study (2017-004335-36) is expected to enroll approximately 120 Parkinson’s patients ages 50 or older with a dementia diagnosis. It is being conducted across several clinical sites in Spain,…
- Anavex 2-73 Trial Recruitment Reaches Halfway Mark March 13, 2019 A Phase 2 trial evaluating the efficacy and safety of investigational Anavex 2-73 as a treatment for Parkinson’s disease dementia has recruited half of its targeted patients, the therapy’s developer, Anavex Life Sciences, has announced. The study is still recruiting Parkinson’s disease patients age 50 or older who have been diagnosed with dementia. The Phase 2 trial is being conducted across several clinical sites in Spain,…
- Parkinson’s Dementia Trial of Oral Anavex 2-73 to Continue with Adjustments April 3, 2020 Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance related to the COVID-19 pandemic. A Phase 2 study of people with dementia linked to Parkinson’s disease is fully enrolled, and the company expects to announce topline results by June. Contingency plans are…
- Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference - GlobeNewswire February 16, 2021 Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
- Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 - Yahoo Finance February 18, 2021 Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 Yahoo Finance
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Being ly-mphatic about drainage issues February 4, 2021 # # # # The lymphatic network is an important part of our body’s defense system. It is made up of an enormous web of vessels and nodes which help to protect us from infection and disease. This network transports a colourless fluid (called lymph), which serves two primary functions: 1.) it contains infection-fighting white blood cells that help in…
- Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference - Yahoo Finance February 16, 2021 Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference Yahoo Finance
- Trying to LIMP-2 the lysosome February 8, 2021 # # # # Lysosomes are small bags of enzymes that are used to break down material inside of cells – digesting newly absorbed food or recycling old/used proteins and rubbish. Recently researchers have been discovering increasing evidence that points towards dysfunction in lysosomes as a key influential player in neurodegenerative conditions, like Parkinson’s. There are several Parkinson’s genetic risk…
- Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson's Disease - StreetInsider.com January 11, 2021 Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson's Disease StreetInsider.com
- Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference - GlobeNewswire April 5, 2019 Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswireNEW YORK, April 05, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer's Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting - GlobeNewswire March 28, 2019 Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer's Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting GlobeNewswireNEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...
- Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer's Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting - GlobeNewswire March 28, 2019 Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer's Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting GlobeNewswireNEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage ...